ALXO Company Profile and Key Details
ALX Oncology Holdings Inc.
ALXO Stock Price Chart
Stock Price Today
ALX Oncology Holdings Inc. (ALXO) stock declined over -2.27%, trading at $1.29 on NASDAQ, down from the previous close of $1.32. The stock opened at $1.30, fluctuating between $1.25 and $1.33 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Company Information
| Employees | 89 |
| Beta | 1.04 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
ALX Oncology Holdings Inc. (NASDAQ: ALXO) stock price is $1.29 in the last trading session. During the trading session, ALXO stock reached the peak price of $1.33 while $1.25 was the lowest point it dropped to. The percentage change in ALXO stock occurred in the recent session was -2.27% while the dollar amount for the price change in ALXO stock was -$0.03.
The NASDAQ listed ALXO is part of Biotechnology industry that operates in the broader Healthcare sector. ALX Oncology Holdings Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Jeanne Y. Jew
Chief Bus. Officer
Dr. Athanasios Tsiatis M.D.
Senior Vice President of Clinical Devel.
Dr. Lin Yeong-Liang M.D., M.S.
Senior Vice President of Drug Safety & Pharmacovigilance
Dr. Corey S. Goodman Ph.D.
Executive Chairman
Dr. Chris Byrd J.D., Ph.D.
Gen. Counsel
Dr. Jaume Pons Ph.D.
Founder, Pres, Chief Executive Officer & Director
Mr. Peter S. Garcia M.B.A.
Chief Financial Officer
Dr. Sophia Randolph M.D., Ph.D.
Chief Medical Officer & Director
Dr. Michael Chang Ph.D.
Vice President of Operations
Dr. Christopher Byrd J.D., Ph.D.
Gen. Counsel
Ms. Shelly Pinto
Vice President of Fin. & Chief Accounting Officer
ALXO's closing price is 8.4% higher than its 52-week low of $1.19 where as its distance from 52-week high of $17.83 is -92.76%.
Number of ALXO employees currently stands at 89.
Official Website of ALXO is: https://www.alxoncology.com
ALXO could be contacted at phone 650 466 7125 and can also be accessed through its website. ALXO operates from 323 Allerton Avenue, South San Francisco, CA 94080, United States.
ALXO stock volume for the day was 555.85K shares. The average number of ALXO shares traded daily for last 3 months was 1.16M.
The market value of ALXO currently stands at $68.04M with its latest stock price at $1.29 and 52.74M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com